147 related articles for article (PubMed ID: 15840596)
1. Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS).
Ramos E; Aróstegui JI; Campuzano S; Rius J; Bousoño C; Yagüe J
Rheumatology (Oxford); 2005 Aug; 44(8):1072-3. PubMed ID: 15840596
[No Abstract] [Full Text] [Related]
2. [Muckle-Wells syndrome: a rare periodic fever syndrome].
Appels CW; Kloppenburg M
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1628-31. PubMed ID: 16901068
[TBL] [Abstract][Full Text] [Related]
3. A cryopyrin-associated periodic syndrome with joint destruction.
Lequerré T; Vittecoq O; Saugier-Veber P; Goldenberg A; Patoz P; Frébourg T; Le Loët X
Rheumatology (Oxford); 2007 Apr; 46(4):709-14. PubMed ID: 17178739
[TBL] [Abstract][Full Text] [Related]
4. Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel.
Frenkel J; Wulffraat NM; Kuis W
Arthritis Rheum; 2004 Nov; 50(11):3738-9; author reply 3739-40. PubMed ID: 15529342
[No Abstract] [Full Text] [Related]
5. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.
Hawkins PN; Lachmann HJ; Aganna E; McDermott MF
Arthritis Rheum; 2004 Feb; 50(2):607-12. PubMed ID: 14872505
[TBL] [Abstract][Full Text] [Related]
6. Beneficial response to interleukin 1 receptor antagonist in traps.
Simon A; Bodar EJ; van der Hilst JC; van der Meer JW; Fiselier TJ; Cuppen MP; Drenth JP
Am J Med; 2004 Aug; 117(3):208-10. PubMed ID: 15300976
[No Abstract] [Full Text] [Related]
7. Interleukin-1beta and the autoinflammatory diseases.
Dinarello CA
N Engl J Med; 2009 Jun; 360(23):2467-70. PubMed ID: 19494224
[No Abstract] [Full Text] [Related]
8. Cryopyrin-associated autoinflammatory syndrome: a new mutation.
Zeft A; Bohnsack JF
Ann Rheum Dis; 2007 Jun; 66(6):843-4. PubMed ID: 17513575
[No Abstract] [Full Text] [Related]
9. [Update in interleukin-1 inhibition].
de Boysson H
Rev Med Interne; 2012 Apr; 33(4):235-7. PubMed ID: 22360831
[No Abstract] [Full Text] [Related]
10. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene.
Matsubayashi T; Sugiura H; Arai T; Oh-Ishi T; Inamo Y
Acta Paediatr; 2006 Feb; 95(2):246-9. PubMed ID: 16449034
[TBL] [Abstract][Full Text] [Related]
11. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism.
Rynne M; Maclean C; Bybee A; McDermott MF; Emery P
Ann Rheum Dis; 2006 Apr; 65(4):533-4. PubMed ID: 16531551
[TBL] [Abstract][Full Text] [Related]
12. A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents.
Matsubara T; Hasegawa M; Shiraishi M; Hoffman HM; Ichiyama T; Tanaka T; Ueda H; Ishihara T; Furukawa S
Arthritis Rheum; 2006 Jul; 54(7):2314-20. PubMed ID: 16802372
[TBL] [Abstract][Full Text] [Related]
13. Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome.
Yamazaki T; Masumoto J; Agematsu K; Sawai N; Kobayashi S; Shigemura T; Yasui K; Koike K
Arthritis Rheum; 2008 Mar; 58(3):864-8. PubMed ID: 18311804
[TBL] [Abstract][Full Text] [Related]
14. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.
Hoffman HM; Rosengren S; Boyle DL; Cho JY; Nayar J; Mueller JL; Anderson JP; Wanderer AA; Firestein GS
Lancet; 2004 Nov 13-19; 364(9447):1779-85. PubMed ID: 15541451
[TBL] [Abstract][Full Text] [Related]
15. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.
Goldbach-Mansky R; Dailey NJ; Canna SW; Gelabert A; Jones J; Rubin BI; Kim HJ; Brewer C; Zalewski C; Wiggs E; Hill S; Turner ML; Karp BI; Aksentijevich I; Pucino F; Penzak SR; Haverkamp MH; Stein L; Adams BS; Moore TL; Fuhlbrigge RC; Shaham B; Jarvis JN; O'Neil K; Vehe RK; Beitz LO; Gardner G; Hannan WP; Warren RW; Horn W; Cole JL; Paul SM; Hawkins PN; Pham TH; Snyder C; Wesley RA; Hoffmann SC; Holland SM; Butman JA; Kastner DL
N Engl J Med; 2006 Aug; 355(6):581-92. PubMed ID: 16899778
[TBL] [Abstract][Full Text] [Related]
16. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome.
Rigante D; Ansuini V; Bertoni B; Pugliese AL; Avallone L; Federico G; Stabile A
Rheumatol Int; 2006 Nov; 27(1):97-100. PubMed ID: 16871408
[TBL] [Abstract][Full Text] [Related]
17. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
Verbsky JW; White AJ
J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
[TBL] [Abstract][Full Text] [Related]
18. Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations.
Touitou I; Perez C; Dumont B; Federici L; Jorgensen C
Ann Rheum Dis; 2006 Nov; 65(11):1530-1. PubMed ID: 17038455
[No Abstract] [Full Text] [Related]
19. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.
Calligaris L; Marchetti F; Tommasini A; Ventura A
Eur J Pediatr; 2008 Jun; 167(6):695-6. PubMed ID: 17588171
[TBL] [Abstract][Full Text] [Related]
20. Two pathogenic CIAS1 mutations and plasma cytokine profile in a Finnish patient with familial cold autoinflammatory syndrome responsive to anakinra.
Kaipiainen-Seppänen O; Punnonen K; van Gijn ME; Mononen T
Scand J Rheumatol; 2008; 37(1):75-6. PubMed ID: 18189199
[No Abstract] [Full Text] [Related]
[Next] [New Search]
